{ "issue_id": "SS-OUTLOOK-2026-10-EVIDENCE-EXPANSION", "version": "1.0.0", "status": "published", "author": "Mike Ye", "prepared_on": "2026-10-14", "published_on": "2026-10-14", "evidence_cutoff": "2026-10-13", "period_start": "2026-10-01", "period_end": "2026-10-13", "dataset_version": "1.0.20", "methodology_version": "1.0.0", "intended_canonical_path": "/ai-data-transactions/outlooks/2026-10-evidence-expansion/", "title": "AI access is expanding faster than observable data-rights pricing", "subtitle": "October 2026 evidence review · 88 canonical AI Access relationships · 15 reviewed strict data-rights observations · three unresolved forecasts", "thesis": "The canonical access register has expanded to 88 relationships, but only twenty carry strict data-rights qualification and fifteen have completed record-level rights review. New deal structures broaden our understanding of governed learning and downstream participation, without establishing a comparable market price for proprietary AI learning rights.", "transaction_ids": [ "SS-AIDT-2025-0001", "SS-AIDT-2026-0004", "SS-AIDT-2026-0007", "SS-AIDT-2025-0002", "SS-AIDT-2026-0008", "SS-AIDT-2026-0009", "SS-AIDT-2026-0010", "SS-AIDT-2026-0011", "SS-AIDT-2026-0012", "SS-AIDT-2026-0013", "SS-AIDT-2026-0014", "SS-AIDT-2026-0015", "SS-AIDT-2026-0016", "SS-AIDT-2026-0018", "SS-AIDT-2026-0017" ], "sections": [ { "heading": "Why 88 access relationships are not 88 priced data-learning deals", "paragraphs": [ "At the October 13, 2026 canonical archive cutoff, Strategic Signal records 88 AI Access relationships. Of these, 83 have completed record-level human review and five legacy cases retain provisional evidence flags. The owner has authorized use of all 88 in this October market-context analysis, not retroactive removal of documented verification gaps.", "Twenty canonical records carry the strict data-rights qualification flag. Fifteen are human-reviewed in corporate AI-data transaction dataset v1.0.20 and five remain provisional. The 88-record universe measures observable breadth of access; it is not a market census, a count of fresh October deals, or a denominator for comparable licensed-data prices. The source is immutable archive 000006 (October 13, 15:22:58 UTC; AI Access ontology v2.0.0, strict data rights v1.0.20, capability catalog v1.0.70)." ], "supporting_transaction_ids": [ "SS-AIDT-2026-0014", "SS-AIDT-2026-0015", "SS-AIDT-2026-0016", "SS-AIDT-2026-0017", "SS-AIDT-2026-0018" ] }, { "heading": "What actually changed in the approved strict-data sample", "paragraphs": [ "The September 30 Outlook froze eleven human-reviewed data-rights records; v1.0.20 now contains fifteen. The four additions are the federated antibody consortium (SS-AIDT-2026-0015; announced September 29), OpenAI–Synopsys (SS-AIDT-2026-0016; September 30), OpenAI–Ironclad (SS-AIDT-2026-0017; October 6), and the Biohub–DOE–NIH initiative (SS-AIDT-2026-0018; October 7). Only two of the fifteen approved strict-data observations were announced October 1–13. Later record approvals of September announcements are coverage expansion, not new October deal flow.", "Historical deals, renewals, contributed proprietary corpora, software-environment learning and program-funded scientific measurement are different asset and contract categories. No market-wide rate or change in industry share can be inferred from the selected sample." ], "supporting_transaction_ids": [ "SS-AIDT-2026-0015", "SS-AIDT-2026-0016", "SS-AIDT-2026-0017", "SS-AIDT-2026-0018" ] }, { "heading": "From source control to governed learning and downstream value", "paragraphs": [ "OneMedNet SS-AIDT-2026-0014 retains source-data rights, licenses clinical model training and derivative-dataset creation, and participates in downstream sublicensing revenue. The federated antibody consortium SS-AIDT-2026-0015 retains participant ownership of proprietary sequences and assay data while enabling controlled shared learning and member-local fine-tuning.", "OpenAI–Synopsys SS-AIDT-2026-0016 licenses expert EDA tool access for model development and discloses a training-subscription plus downstream GPT-Synopsys revenue-share structure; it expressly excludes customer data from training. OpenAI–Ironclad SS-AIDT-2026-0017 makes expert rubrics and hosted professional workflows available for synthetic-task reinforcement learning, without transferring private customer contracts.", "Biohub SS-AIDT-2026-0018 establishes a different temporal right: commercially funded biology data carries an initial one-year early-access embargo for participating funders, before intended public release. Government-funded resources are not governed by the same embargo. These arrangements cannot all be characterized as raw-data sales." ], "supporting_transaction_ids": [ "SS-AIDT-2026-0014", "SS-AIDT-2026-0015", "SS-AIDT-2026-0016", "SS-AIDT-2026-0017", "SS-AIDT-2026-0018" ] }, { "heading": "Commercial structures are becoming clearer; comparable prices are not", "paragraphs": [ "Historical Tempus–Pathos SS-AIDT-2025-0002 identifies $200 million in contractual data-license fees across three years with potential equity settlement; historical Tempus–Recursion SS-AIDT-2026-0012 specifies $42 million in later amended scheduled license fees. Silencio SS-AIDT-2026-0009 discloses a September 7 $250,000 voice-data contract. Their corpus, scope and payment terms are not comparable.", "OneMedNet's newer agreement is described as seven figures, but exact amount, currency and settlement form are not established by the reviewed announcement. Synopsys discloses training subscription and revenue sharing, without numerical amounts. Biohub's $300 million commercial contribution finances a time-limited data advantage within a broader research initiative, not a standalone purchased dataset. The widely cited $1.8 billion encompasses public and philanthropic components. Do not aggregate these amounts or present a price multiple, revenue run rate or proprietary-data valuation range." ], "supporting_transaction_ids": [ "SS-AIDT-2025-0002", "SS-AIDT-2026-0009", "SS-AIDT-2026-0012", "SS-AIDT-2026-0014", "SS-AIDT-2026-0016", "SS-AIDT-2026-0018" ] }, { "heading": "Market projection: rights usability, participation, and the industrial gap", "paragraphs": [ "Strategic Signal analysis: the more durable question is whether AI companies gain only governed retrieval and workflow access, enforceable learning and derivative-model permissions, or explicit downstream economic participation. None of these stages automatically establishes a realizable asset price.", "The OneMedNet sublicensing model and GPT-Synopsys shared-product economics are distinct downstream-value examples, not yet market prevalence evidence. The October 2 Frontier Value Capture baseline remains a separate, unchanged forecast. For new industries, engineering software and biological measurement now have concrete records; manufacturing-process and equipment-maintenance histories still require directly qualifying transactions.", "M&A diligence should underwrite underlying ownership, permission to train, retention and exclusivity, derived-model rights, restrictions, refresh obligations, and the consideration allocated to each. Scarcity alone without enforceable usability is not a valuation." ], "supporting_transaction_ids": [ "SS-AIDT-2026-0014", "SS-AIDT-2026-0015", "SS-AIDT-2026-0016", "SS-AIDT-2026-0017", "SS-AIDT-2026-0018" ] }, { "heading": "September forecast scorecard: all three calls remain unresolved", "paragraphs": [ "SS-FC-2026-001: OneMedNet, the federated antibody consortium and Synopsys provide post-issuance retained-control learning structures. Ironclad and Biohub add potential examples but cannot be counted automatically under the original requirement for classifiable ownership terms. The forecast's at-least-five-eligible-observation and horizon-end majority test has not been satisfied.", "SS-FC-2026-002: No two unrelated manufacturing or equipment-maintenance data owners with explicit new model-learning rights are established. The historical provisional Caterpillar item is ineligible; semiconductor design tools and cellular science do not substitute for manufacturing and maintenance records.", "SS-FC-2026-003: The original requirement is distinguishable amount, currency, consideration scope and payment form for a qualifying newly announced data-learning-rights arrangement. OneMedNet, Synopsys and Biohub do not collectively or individually supply the necessary eligible allocated monetary evidence. These original September 16 calls retain their September 17, 2026–September 16, 2027 observation horizon, definitions and prior dated observations." ], "supporting_transaction_ids": [ "SS-AIDT-2026-0014", "SS-AIDT-2026-0015", "SS-AIDT-2026-0016", "SS-AIDT-2026-0017", "SS-AIDT-2026-0018" ] } ], "forecasts": [ { "forecast_id": "SS-FC-2026-001", "version": "1.0.0", "status": "unresolved", "issued_on": "2026-09-16", "prepared_on": "2026-09-16", "evidence_cutoff": "2026-09-16", "horizon_start": "2026-09-17", "horizon_end": "2027-09-16", "intended_canonical_path": "/ai-data-transactions/outlooks/2026-09-baseline/#ss-fc-2026-001", "thesis": "The next sufficiently observable cohort will favor learning licenses, controlled access and co-development over outright data ownership transfers.", "mechanism": "Continuing owners can monetize or benefit from learning while retaining operational access and protecting confidential source data.", "scope": "Newly announced, subsequently human-approved transactions within the horizon; exclude historical backfill and updates to existing deals.", "supporting_transaction_ids": [ "SS-AIDT-2025-0001", "SS-AIDT-2025-0002", "SS-AIDT-2026-0004", "SS-AIDT-2026-0007" ], "assumptions": [ "Meaningful training permission can be separated from ownership.", "Public disclosure will describe enough rights to classify at least five future observations." ], "alternative": "Distressed archive sales or exclusive dataset acquisitions become the more observable transaction form.", "confidence": "moderate", "confidence_rationale": "All four opening cases fit the mechanism, but the sample is selected and small.", "confirmation": "At horizon end, at least five approved new observations have classifiable ownership terms and more than half explicitly use licenses, local learning or controlled access without a disclosed transfer of underlying data ownership.", "invalidation": "With at least five classifiable observations, half or fewer meet that test.", "unresolved": "Fewer than five observations have sufficiently clear rights. Unspecified ownership is not counted as retained ownership.", "outcome_observations": [ { "observed_on": "2026-09-30", "status": "unresolved", "assessment": "Interim unresolved. OneMedNet is one conservative eligible new classifiable observation. Exclude Harell under the corrected September 15 source-stated first-disclosure treatment, GuideAI as a renewal, and pre-horizon backfill. Threshold of at least five and horizon-end majority test are not met.", "supporting_transaction_ids": [ "SS-AIDT-2026-0011", "SS-AIDT-2026-0013", "SS-AIDT-2026-0014", "SS-AIDT-2026-0009", "SS-AIDT-2026-0012" ] }, { "observed_on": "2026-10-13", "status": "unresolved", "assessment": "Interim unresolved: OneMedNet, the antibody federation and OpenAI-Synopsys supply retained-control learning evidence, but enough new observations with classifiable ownership terms and the horizon-end majority are not established. Ironclad and Biohub require conservative treatment.", "supporting_transaction_ids": [ "SS-AIDT-2026-0014", "SS-AIDT-2026-0015", "SS-AIDT-2026-0016", "SS-AIDT-2026-0017", "SS-AIDT-2026-0018" ] } ], "canonical_path": "/ai-data-transactions/outlooks/2026-09-baseline/#ss-fc-2026-001" }, { "forecast_id": "SS-FC-2026-002", "version": "1.0.0", "status": "unresolved", "issued_on": "2026-09-16", "prepared_on": "2026-09-16", "evidence_cutoff": "2026-09-16", "horizon_start": "2026-09-17", "horizon_end": "2027-09-16", "intended_canonical_path": "/ai-data-transactions/outlooks/2026-09-baseline/#ss-fc-2026-002", "thesis": "At least two unrelated industrial data owners will announce qualifying learning-rights arrangements involving manufacturing or equipment-maintenance histories.", "mechanism": "Expensive failures and repeated interventions can provide task-specific learning examples that generic public text does not reproduce.", "scope": "Manufacturing process, quality/yield, industrial equipment or maintenance corpora; exclude software-only archives, ordinary deployments and two announcements from the same owner group.", "supporting_transaction_ids": [ "SS-AIDT-2026-0007" ], "assumptions": [ "Owners can link records to interventions or outcomes.", "At least some owners can grant usable learning rights and disclose the arrangement." ], "alternative": "Learning stays internal or agreements disclose only software deployment, leaving no qualifying observable rights transaction.", "confidence": "low", "confidence_rationale": "An adjacent energy precedent supports the logic, but the approved baseline has no direct manufacturing precedent.", "confirmation": "By horizon end, two qualifying announcements within the horizon from unrelated owner groups are approved with explicit model-learning use.", "invalidation": "After a documented horizon-end sector search, fewer than two qualifying announcements are found. This misses the observable-deal prediction, not proof that private arrangements do not exist.", "unresolved": "Evidence or final sector search remains incomplete; no automatic success based on deployment announcements.", "outcome_observations": [ { "observed_on": "2026-09-30", "status": "unresolved", "assessment": "Interim unresolved. Zero qualifying approved manufacturing or equipment-maintenance arrangements from unrelated owner groups in this snapshot. No horizon-end sector search has occurred; do not infer failure or absence of private deals.", "supporting_transaction_ids": [ "SS-AIDT-2026-0011", "SS-AIDT-2026-0013", "SS-AIDT-2026-0014", "SS-AIDT-2026-0009", "SS-AIDT-2026-0012" ] }, { "observed_on": "2026-10-13", "status": "unresolved", "assessment": "Interim unresolved: there are not two qualifying new model-learning deals from unrelated manufacturing or equipment-maintenance data owners. The historical provisional Caterpillar record is excluded; engineering-tool and biology arrangements do not meet this forecast scope.", "supporting_transaction_ids": [ "SS-AIDT-2026-0014", "SS-AIDT-2026-0015", "SS-AIDT-2026-0016", "SS-AIDT-2026-0017", "SS-AIDT-2026-0018" ] } ], "canonical_path": "/ai-data-transactions/outlooks/2026-09-baseline/#ss-fc-2026-002" }, { "forecast_id": "SS-FC-2026-003", "version": "1.0.0", "status": "unresolved", "issued_on": "2026-09-16", "prepared_on": "2026-09-16", "evidence_cutoff": "2026-09-16", "horizon_start": "2026-09-17", "horizon_end": "2027-09-16", "intended_canonical_path": "/ai-data-transactions/outlooks/2026-09-baseline/#ss-fc-2026-003", "thesis": "At least one newly announced transaction will disclose consideration specifically allocated to proprietary corporate data learning rights, adding a pricing reference beyond Tempus.", "mechanism": "Explicit licenses create payment obligations that may appear in filings or transaction announcements even when larger programs bundle services and compute.", "scope": "A new owner/buyer arrangement announced within the horizon; disclosed amount, currency, consideration scope and payment form must be distinguishable. No minimum dollar threshold.", "supporting_transaction_ids": [ "SS-AIDT-2025-0002", "SS-AIDT-2026-0007" ], "assumptions": [ "Some counterparties disclose the license leg separately.", "A monetary allocation reflects a data right rather than merely a total program budget." ], "alternative": "Material rights remain hidden inside co-development, equity or service agreements without separate pricing.", "confidence": "low", "confidence_rationale": "One clear historical allocation establishes possibility, not its future frequency or price level.", "confirmation": "At least one approved transaction meeting scope is supported by a filing, contract or company disclosure before horizon end.", "invalidation": "No such transaction is found after a documented horizon-end pricing search. A bundled headline or pending bid does not satisfy the test.", "unresolved": "Source access or final search is incomplete. A subsequently discovered pre-horizon deal is historical backfill and cannot count.", "outcome_observations": [ { "observed_on": "2026-09-30", "status": "unresolved", "assessment": "Interim unresolved. OneMedNet supplies directional support for separately material data-license consideration but the reviewed release does not state explicit currency or settlement form. Do not add a new exact-price or named-buyer requirement: neither is stated in the original forecast. Silencio and Tempus–Recursion are excluded pre-horizon/historical arrangements.", "supporting_transaction_ids": [ "SS-AIDT-2026-0011", "SS-AIDT-2026-0013", "SS-AIDT-2026-0014", "SS-AIDT-2026-0009", "SS-AIDT-2026-0012" ] }, { "observed_on": "2026-10-13", "status": "unresolved", "assessment": "Interim unresolved: OneMedNet does not disclose currency or payment form, Synopsys does not disclose allocated amounts, and Biohub's commercial payments are tied to a bundled scientific program, not a separately priced qualifying data license. Historical pricing references cannot confirm a post-issuance forecast.", "supporting_transaction_ids": [ "SS-AIDT-2026-0014", "SS-AIDT-2026-0015", "SS-AIDT-2026-0016", "SS-AIDT-2026-0017", "SS-AIDT-2026-0018" ] } ], "canonical_path": "/ai-data-transactions/outlooks/2026-09-baseline/#ss-fc-2026-003" } ], "review_protocol": "Owner authorized the October evidence-expansion Outlook and instructed publication through existing GitHub connectors. Preserve immutable prior forecasts and append dated assessments; freeze strict dataset v1.0.20 and archive 000006 for broad AI Access context.", "limitations": [ "Registry breadth is research coverage, not evidence of market population or growth rate.", "At the frozen 88-record cutoff, 83 records were human-reviewed and five retained source-evidence limitations, even after the owner authorized inclusion in editorial context.", "The strict rights set has twenty flagged records but only fifteen completed record-level reviews; five provisional legacy records are excluded from approved benchmarks.", "Two strict-data observations were announced October 1–13; later approvals of older announcements are not new October deals.", "Bundled contributions, noncash/equity terms, renewal fees and revenue-share structures are not automatically comparable dataset prices.", "No source-supported valuation range, industry share, price-per-corpus estimate, or forecast hit rate is calculated.", "The three original forecasts expire September 16, 2027 and remain unresolved. The October 2 Frontier Value Capture issue is separate." ], "canonical_path": "/ai-data-transactions/outlooks/2026-10-evidence-expansion/", "publication_review": { "status": "human_reviewed", "reviewer": "Mike Ye", "approval_channel": "owner_conversation", "reviewed_at": "2026-10-14", "approved_draft_sha256": "fb7a98cfb6d0f81332d240cb348617c6b432184fea77ecb1590e8f06e6db7255" } }